CYTH – cyclo therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Niemann-Pick Disease Type C Market Insight, Epidemiology and Market Forecast - 2032, Featuring Zevra Therapeutics, Azafaros, Cyclo Therapeutics and IntraBio [Yahoo! Finance]
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $3.00 price target on the stock.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) is now covered by analysts at Ascendiant Capital Markets. They set a "buy" rating and a $2.60 price target on the stock.
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Form 10-Q Cyclo Therapeutics, Inc. For: Mar 31
Form 10-K/A Cyclo Therapeutics, Inc. For: Dec 31
Form 10-K Cyclo Therapeutics, Inc. For: Dec 31
Form 8-K/A Cyclo Therapeutics, Inc. For: Dec 27
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.